09:04 AM EDT, 10/17/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that Imfinzi (durvalumab) and standard-of-care chemotherapy reduced the risk of death by 22% compared to chemotherapy alone in a phase III trial to treat early gastric cancer.

The company said that in the final overall survival analysis, an estimated 69% of patients treated with the Imfinzi-based regimen were alive at three years, compared with 62% for standard-of-care chemotherapy.